A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II).

Trial Profile

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2013

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sepantronium bromide (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Mar 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 12 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top